April 27, 2020 / 12:26 PM / a month ago

BRIEF-Adverum Biotechnologies Doses First Patient In Cohort 4 Of OPTIC Phase 1 Clinical Trial Of ADVM-022

April 27 (Reuters) - Adverum Biotechnologies Inc:

* ADVERUM BIOTECHNOLOGIES DOSES FIRST PATIENT IN COHORT 4 OF OPTIC PHASE 1 CLINICAL TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below